Author:
Jia Jia,Mao Lili,Lin Jing,Li Wenyu,Yuan Pei,Guo Lei,Dai Jie,Li Caili,Bai Xue,Li Zhongwu,Chen Yu,Guo Jun,Ying Jianming,Si Lu
Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Jeong SH, Hyeong JH, Park EJ, Kim KJ, Kim KH. Human epidermal growth factor receptor 2 expression in extramammary Paget’s disease and mammary Paget’s disease. Australas J Dermatol 2022; 63(1): 115–118
2. Angelico G, Santoro A, Inzani F, Straccia P, Arciuolo D, Mulè A, Valente M, Spadola S, D’Alessandris N, Garganese G, Cianfrini F, Piermattei A, Scambia G, Zannoni GF. Hormonal environment and HER2 status in extra-mammary Paget’s disease (eMPD): a systematic literature review and meta-analysis with clinical considerations. Diagnostics (Basel) 2020; 10(12): 1040
3. Sekiguchi N, Kubota S, Noguchi T, Fukushima T, Kobayashi T, Kanda S, Koizumi T, Miyake T, Shirai T, Okuyama R. Experiences of trastuzumab plus paclitaxel combination therapy in metastatic human epidermal growth factor receptor 2-positive extramammary Paget’s disease: four cases and a review. J Dermatol 2020; 47(11): 1276–1279
4. National Medical Products Administration. Disitamab vedotin: NMPA Approval notice. 2021, available from the website of NMPA
5. RemeGen. Disitamab vedotin: Chinese prescribing information. Yantai. 2021